Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane plus gemcitabine vs gemcitabine alone in unresectable locally advanced pancreatic cancer
2013-002973-23Phase 2Active
- Sponsor
- Fondazione GISCAD
- Start
- Sep 2013
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial in pancreatic cancer (PC) comparing Abraxane plus gemcitabine with Gemcitabine alone (2 arms). Primary endpoint: Progression rate. Started Sep 2013; status: active.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2013-002973-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002973-23.